Page 1

Genmab Genmab Announces Financial Results for the First Nine Months of 2021 November 10 , 2021 ; Copenhagen , Denmark ; Interim Report for the First Nine Months Ended September 30 , 2021 Highlights The U.S. Food and Drug Administration ( U.S. FDA ) granted Genmab and Seagen Inc. ( Seagen ) accelerated Approval for TIVDAKTM ( tisotumab vedotin - tftv ) for patients with recurrent or metastatic cervical cancer ● DARZALEX® net sales as reported by Johnson & Johnson increased 49 % compared to the first nine months of 2020 to USD 4,378 million , resulting in royalty income of DKK 4,167 million Genmab improves its 2021 financial guidance " The U.S. FDA approval for TIVDAK represents an important milestone both for the treatment of cervical cancer as well as for Genmab as a company , " said Jan van de Winkel , Ph.D. , Chief Executive Officer of Genmab . " TIVDAK is the first and only approved antibody - drug conjugate ( ADC ) for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy , providing a new treatment option for patients impacted by this devastating disease . The decision by the U.S. FDA also marks the first regulatory approval for an ADC combining Genmab's antibody with Seagen's ADC technology and is the first approval for any therapy owned at least 50 % by Genmab . This achievement was only possible because of the efforts of our dedicated and talented team , the excellent collaboration with our partner for TIVDAK , Seagen , and the patients , families and caregivers as well as the nurses , physicians and study teams who participated in our clinical trials . " Financial Performance First Nine Months of 2021 Net sales of DARZALEX by Janssen Biotech Inc. ( Janssen ) were USD 4,378 million in the first nine months of 2021 compared to USD 2,937 million in the first nine months of 2020 , an increase of USD 1,441 million , or 49 % . Royalty revenue was DKK 4,698 million in the first nine months of 2021 compared to DKK 3,090 million in the first nine months of 2020 , an increase of DKK 1,608 million , or 52 % . The increase was driven by higher net sales of DARZALEX , TEPEZZA® and Kesimpta® resulting in higher royalties . Total revenue was DKK 5,863 million in the first nine months of 2021. In addition to the royalty revenue described above , Genmab also recognized DKK 794 million of milestone revenue during the first nine months of 2021. Revenue for the first nine months of 2020 was DKK 8,067 million and included the one - time upfront payment of DKK 4,398 million recognized as license revenue from AbbVie Inc. ( AbbVie ) pursuant to our collaboration announced in June 2020 . Operating expenses were DKK 3,654 million in the first nine months of 2021 compared to DKK 2,641 million in the first nine months of 2020. The increase of DKK 1,013 million , or 38 % , was driven by the continued advancement of multiple pipeline projects , the increase in new employees to support the launch of TIVDAK and expansion of our product pipeline , as well as the continued development of commercialization capabilities and Genmab's broader organizational infrastructure . Operating result was DKK 2,209 million in the first nine months of 2021 compared to DKK 5,426 million in the first nine months of 2020. The decrease of DKK 3,217 million , or 59 % , was driven by lower revenue as a result of the non - recurring license revenue in 2020 associated with the upfront payment from AbbVie and increased operating expenses . Genmab A / S Kalvebod Brygge 43 1560 Copenhagen V , Denmark Tel : +45 7020 2728 Fax : +45 7020 2729 www.genmab.com Company Announcement no . 67 Page 1/38 CVR no . 2102 3884